BMS's daclatasvir is first in class to garner CHMP nod
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb's daclatasvir has been given a positive opinion by the panel that recommends on new drugs in the EU as a treatment for hepatitis C in combination with other therapies. Daclatasvir (under the brand name Daklinza) is the first NS5A complex inhibitor to receive a positive opinion. However, it cannot afford to rest on its laurels, as strong rivals are not far behind.